BerGenBio to Participate in Carnegie Nordic Healthcare Seminar

BERGEN, Norway, March 4, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will present at Carnegie’s 27th Annual Nordic Healthcare Seminar to be held on March 5th - 6th, 2024 in Stockholm, Sweden.

 

The presentation will be live streamed by Carnegie on March 6th from 9:40 am CET. The presentation will also be made available on the Company website in the Investor/presentations section following the presentation. 

 

www.bergenbio.com/investors/presentations/ 

 

 

 

-End-

 

 

Contacts

 

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

 

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

 

Media Relations

 

Jan Lilleby

jl@lillebyfrisch.no

 

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.

 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

 

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.